Labcorp Holdings Inc. $LH Stock Position Raised by D.A. Davidson & CO.

D.A. Davidson & CO. increased its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 17.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,575 shares of the medical research company’s stock after acquiring an additional 2,824 shares during the quarter. D.A. Davidson & CO.’s holdings in Labcorp were worth $4,956,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Labcorp during the fourth quarter valued at approximately $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Labcorp in the 4th quarter worth approximately $27,000. JPL Wealth Management LLC bought a new stake in shares of Labcorp in the 3rd quarter worth approximately $28,000. Eagle Bay Advisors LLC acquired a new position in Labcorp during the 4th quarter valued at approximately $29,000. Finally, DV Equities LLC acquired a new position in Labcorp during the 4th quarter valued at approximately $29,000. Institutional investors own 95.94% of the company’s stock.

Labcorp Stock Performance

Shares of NYSE LH opened at $283.63 on Friday. Labcorp Holdings Inc. has a 12-month low of $241.81 and a 12-month high of $293.72. The company has a market cap of $23.26 billion, a PE ratio of 25.12, a P/E/G ratio of 1.88 and a beta of 0.89. The stock has a 50 day simple moving average of $266.22 and a 200-day simple moving average of $267.91. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68.

Labcorp (NYSE:LH) last posted its earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.09 by $0.16. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, equities research analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is 25.51%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LH. Robert W. Baird upped their price objective on Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Evercore reissued an “outperform” rating and set a $300.00 price target on shares of Labcorp in a report on Wednesday, April 8th. Bank of America upped their price target on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $314.40.

Insider Activity

In related news, EVP Kathryn W. Kyle sold 762 shares of Labcorp stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the sale, the executive vice president directly owned 3,813 shares in the company, valued at $1,006,212.57. The trade was a 16.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the sale, the chief executive officer directly owned 107,234 shares of the company’s stock, valued at $27,291,053. The trade was a 5.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 6,991 shares of company stock valued at $1,796,696. Company insiders own 0.84% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.